ArticleCardiovascular diabetology2026
Novel amino acid and fatty acid signatures linked to type 2 diabetes risk after gestational diabetes mellitus.
Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundWomen with gestational diabetes mellitus (GDM) history carry increased risks of type 2 diabetes compared to women without GDM history. This study aims to identify the dysregulated metabolic pathways and metabolite signatures during pregnancy that predict the risk of developing type 2 diabetes post-GDM.
methods101 Hispanic women with GDM diagnoses were followed from the 3rd trimester of index pregnancy to 12 years post-delivery. Oral and intravenous glucose tolerance tests were performed every 12–15 months until development of type 2 diabetes, lost-to-follow-up or the end of the study. Type 2 diabetes incidence was identified as a fasting glucose concentration ≥ 126 mg/dL or 2-hour glucose ≥ 200 mg/dL. In this study, archived plasma samples from the 3rd trimester of pregnancy were assayed for untargeted metabolomics using mass-spectrometry to explore metabolic signatures of diabetes development. Metabolome-wide association analysis was performed to assess the association of metabolomic features with type 2 diabetes incidence using Cox proportional hazards models adjusted for age at delivery, along with post-delivery body mass index, additional pregnancy, and self-reported daily calorie intake at each follow-up visit as time-varying covariates, followed by Mummichog pathway enrichment analysis.
resultsAmong the 101 women, 52 developed diabetes in 12 years. Metabolomics analysis suggested that nine amino acid and fatty acid metabolic pathways were associated with the risk of developing type 2 diabetes in GDM women (p-values of pathway enrichment tests < 0.05). Higher plasma levels of agmatine, hydroxyproline/5-aminolevulinate, along with lower plasma levels of threonine/homoserine, 25-hydroxycholesterol, FA12:0 (laurate), FA20:0 (arachidic acid), FA20:3 (homolinoleic acid), FA18:3 n-3 or n-6 (linolenic acid) in 3rd trimester were associated with a 12%–60% higher hazard of developing type 2 diabetes during the up to 12 years’ post-delivery period (all p-values < 0.05).
conclusionLevels of amino acid and fatty acid metabolomic signatures in pregnancy may help identify individuals at an elevated risk of developing type 2 diabetes after GDM-complicated pregnancy, highlighting opportunities for earlier, more targeted prevention that require confirmation in larger, prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.